Belgium-biotech Imcyse is developing IMCY-0098, spinoff intellectual property developed at KU Leuven. A recent Phase I trial enrolled 41 patients newly diagnosed with type 1 diabetes. The investigational drug not only met its endpoint safely but also revealed...